[Correlation Between the Level of the Urinary 11-Dehydrothromboxane B2 and the Clinical Efficacy of Aspirin in Patients with Type 2 Diabetes and Coronary Artery Disease].

Teng-fei Liu,Jing-wei Zhang,Xia-huan Chen,Xue-ru Feng,Zhong-sheng Bai,Mei-lin Liu
DOI: https://doi.org/10.3969/j.issn.1671-167x.2015.06.006
2015-01-01
Abstract:OBJECTIVE:To elucidate the correlation between urinary 11-dehydro-thromboxane B2 (11dhTxB2) and clinical efficacy of aspirin treatment in patients with type 2 diabete and coronary artery disease (CAD).METHODS:In this prospective cohort study, 169 aged patients with type 2 diabete accompanying CAD in Peking University First Hospital were enrolled. The level of urinary 11dhTxB2 was detected using enzyme-linked immuno-sorbent assay. Low aspirin response or high on aspirin platelet reactivity (HAPR) was defined as urinary 11dhTxB2>1 500 ng/g. All the included patients were divided into two groups based on the results, HAPR group and No-HAPR group.RESULTS:Baseline urinary 11dhTxB2 of the patients with type 2 diabete accompanying CAD was (3 687±3 052) ng/g, while the urinary 11dhTxB2 was (1 954±859) ng/g in patients after 100 mg/d aspirin treatment (P<0.001). Prevalence of HAPR in patients with type 2 diabete accompanying CAD were 32.5%. Within a mean follow-up time of 12 months, the outcomes occurred more frequently in HAPR group than in No-HAPR group (P<0.05).CONCLUSION:Urinary 11dhTxB2 can be recognized as an effective indicator in evaluating aspirin clinical efficacy of patients with type 2 diabete accompanying CAD.
What problem does this paper attempt to address?